Stacey T. Long

530 total citations
17 papers, 435 citations indexed

About

Stacey T. Long is a scholar working on Molecular Biology, Pharmacology and Physical and Theoretical Chemistry. According to data from OpenAlex, Stacey T. Long has authored 17 papers receiving a total of 435 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 4 papers in Pharmacology and 3 papers in Physical and Theoretical Chemistry. Recurrent topics in Stacey T. Long's work include Bone Metabolism and Diseases (9 papers), Natural product bioactivities and synthesis (8 papers) and Biochemical and Structural Characterization (5 papers). Stacey T. Long is often cited by papers focused on Bone Metabolism and Diseases (9 papers), Natural product bioactivities and synthesis (8 papers) and Biochemical and Structural Characterization (5 papers). Stacey T. Long collaborates with scholars based in United States and United Kingdom. Stacey T. Long's co-authors include Arup Roy, Lawrence X. Yu, Mark D. Coffin, Joseph W. Polli, Larry R. Miller, David N. Deaton, Lois L. Wright, Kevin J. Wells‐Knecht, Aaron B. Miller and John G. Catalano and has published in prestigious journals such as Journal of Medicinal Chemistry, Pharmaceutical Research and Journal of Pharmaceutical Sciences.

In The Last Decade

Stacey T. Long

17 papers receiving 418 citations

Peers

Countries citing papers authored by Stacey T. Long

Since Specialization

Citations

This map shows the geographic impact of Stacey T. Long's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stacey T. Long with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stacey T. Long more than expected).

Fields of papers citing papers by Stacey T. Long

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stacey T. Long. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stacey T. Long. The network helps show where Stacey T. Long may publish in the future.

Co-authorship network of co-authors of Stacey T. Long

This figure shows the co-authorship network connecting the top 25 collaborators of Stacey T. Long. A scholar is included among the top collaborators of Stacey T. Long based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stacey T. Long. Stacey T. Long is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	The Degradation Chemistry of Farglitazar and Elucidation of the Oxidative Degradation Mechanisms 2016 ·Journal of Pharmaceutical Sciences ·Dan W. Reynolds, John M. Campbell, (unknown), Biren K. Joshi, Kevin L. Facchine, Stacey T. Long, Thomas M. O’Connell, (unknown), (unknown), (unknown), Andrew M. Wolters	3
2	Enantiotropically-related polymorphs of {4-(4-chloro-3-fluorophenyl)-2-[4-(methyloxy)phenyl]-1,3-thiazol-5-yl} acetic acid: Crystal structures and multinuclear solid-state NMR 2008 ·Journal of Pharmaceutical Sciences ·Frederick G. Vogt, (unknown), Stacey T. Long, (unknown), Robert A. Carlton, (unknown), (unknown), Royston C. B. Copley, Mark E. Light	22
3	Novel, potent P2–P3 pyrrolidine derivatives of ketoamide-based cathepsin K inhibitors 2006 ·Bioorganic & Medicinal Chemistry Letters ·David G. Barrett, John G. Catalano, David N. Deaton, Anne M. Hassell, Stacey T. Long, Aaron B. Miller, Larry R. Miller, John A. Ray, Vicente Sámano, Lisa M. Shewchuk, Kevin J. Wells‐Knecht, Derril H. Willard, Lois L. Wright	16
4	Acyclic, orally bioavailable ketone-based cathepsin K inhibitors 2006 ·Bioorganic & Medicinal Chemistry Letters ·David G. Barrett, John G. Catalano, David N. Deaton, Stacey T. Long, Robert B. McFadyen, Aaron B. Miller, Larry R. Miller, Vicente Sámano, Francis X. Tavares, Kevin J. Wells‐Knecht, Lois L. Wright, Huiqiang Zhou	6
5	Semicarbazone-based inhibitors of cathepsin K, are they prodrugs for aldehyde inhibitors? 2005 ·Bioorganic & Medicinal Chemistry Letters ·(unknown), David G. Barrett, David N. Deaton, Robert T. Gampe, Anne M. Hassell, Stacey T. Long, Robert B. McFadyen, Aaron B. Miller, Larry R. Miller, (unknown), Lisa M. Shewchuk, Kevin J. Wells‐Knecht, Derril H. Willard, Lois L. Wright	12
6	A structural screening approach to ketoamide-based inhibitors of cathepsin K 2005 ·Bioorganic & Medicinal Chemistry Letters ·David G. Barrett, John G. Catalano, David N. Deaton, Stacey T. Long, Robert B. McFadyen, Aaron B. Miller, Larry R. Miller, Kevin J. Wells‐Knecht, Lois L. Wright	12
7	P2–P3 conformationally constrained ketoamide-based inhibitors of cathepsin K 2005 ·Bioorganic & Medicinal Chemistry Letters ·David G. Barrett, (unknown), John G. Catalano, David N. Deaton, Anne M. Hassell, Cynthia H. Jurgensen, Stacey T. Long, Robert B. McFadyen, Aaron B. Miller, Larry R. Miller, (unknown), John A. Ray, Vicente Sámano, Lisa M. Shewchuk, Francis X. Tavares, Kevin J. Wells‐Knecht, Derril H. Willard, Lois L. Wright, Huiqiang Zhou	27
8	Potent and selective P2–P3 ketoamide inhibitors of cathepsin K with good pharmacokinetic properties via favorable P1′, P1, and/or P3 substitutions 2004 ·Bioorganic & Medicinal Chemistry Letters ·David G. Barrett, John G. Catalano, David N. Deaton, Anne M. Hassell, Stacey T. Long, Aaron B. Miller, Larry R. Miller, Lisa M. Shewchuk, Kevin J. Wells‐Knecht, Derril H. Willard, Lois L. Wright	24
9	Orally bioavailable small molecule ketoamide-based inhibitors of cathepsin K 2004 ·Bioorganic & Medicinal Chemistry Letters ·David G. Barrett, John G. Catalano, David N. Deaton, Stacey T. Long, Larry R. Miller, Francis X. Tavares, Kevin J. Wells‐Knecht, Lois L. Wright, Huiqiang Zhou	10
10	Design of Small Molecule Ketoamide‐Based Inhibitors of Cathepsin K. 2004 ·ChemInform ·John G. Catalano, David N. Deaton, Stacey T. Long, Robert B. McFadyen, Larry R. Miller, (unknown), Kevin J. Wells‐Knecht, Lois L. Wright	1
11	Design of small molecule ketoamide-based inhibitors of cathepsin K 2003 ·Bioorganic & Medicinal Chemistry Letters ·John G. Catalano, David N. Deaton, Stacey T. Long, Robert B. McFadyen, Larry R. Miller, (unknown), Kevin J. Wells‐Knecht, Lois L. Wright	19
12	Design of Potent, Selective, and Orally Bioavailable Inhibitors of Cysteine Protease Cathepsin K 2003 ·Journal of Medicinal Chemistry ·Francis X. Tavares, (unknown), David N. Deaton, Anne M. Hassell, Stacey T. Long, Aaron B. Miller, (unknown), Larry R. Miller, Lisa M. Shewchuk, Kevin J. Wells‐Knecht, Derril H. Willard, Lois L. Wright, Huiqiang Zhou	37
13	Dehydration, hydration behavior, and structural analysis of fenoprofen calcium*This work is presented in memory of one of the authors, Jia Xu. 2001 ·Journal of Pharmaceutical Sciences* ·(unknown), (unknown), (unknown), Stacey T. Long, Chris Kidd	37
14	Crystal Structure Prediction for Eniluracil 2001 ·Journal of Pharmaceutical Sciences ·Mark Sacchetti, (unknown), Stacey T. Long, Robert W. Lancaster	4
15	Vitamin E-TPGS Increases Absorption Flux of an HIV Protease Inhibitor by Enhancing Its Solubility and Permeability1 1999 ·Pharmaceutical Research ·Lawrence X. Yu, (unknown), Joseph W. Polli, (unknown), Stacey T. Long, Arup Roy, (unknown), Mark D. Coffin	196
16	Environmentally controlled sample stage for Scintag's six-position XRD sample changer 1999 ·Powder Diffraction ·(unknown), C. Kidd, Stacey T. Long, (unknown), (unknown)	3
17	Excipient compatibility as assessed by isothermal microcalorimetry 1998 ·Journal of Pharmacy and Pharmacology ·(unknown), (unknown), Stacey T. Long, (unknown)	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact